Clinical Trial

Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Name: Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients — clinical trial record (NCT07365358)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EMPAGO

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Trial Details

NCT Number	NCT07365358
Lead Sponsor	Chong Kun Dang Pharmaceutical
Conditions	Diabete Type 2
Enrollment	200 participants
Start Date	2026-03
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-01-26